Cargando…
CPPF, A Novel Microtubule Targeting Anticancer Agent, Inhibits the Growth of a Wide Variety of Cancers
In the past, several microtubule targeting agents (MTAs) have been developed into successful anticancer drugs. However, the usage of these drugs has been limited by the acquisition of drug resistance in many cancers. Therefore, there is a constant demand for the development of new therapeutic drugs....
Autores principales: | Han, Ho Jin, Park, Chanmi, Hwang, Joonsung, N.R., Thimmegowda, Kim, Sun-Ok, Han, Junyeol, Woo, Minsik, B, Shwetha, Ryoo, In-Ja, Lee, Kyung Ho, Cha-Molstad, Hyunjoo, Kwon, Yong Tae, Kim, Bo Yeon, Soung, Nak-Kyun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7370279/ https://www.ncbi.nlm.nih.gov/pubmed/32645923 http://dx.doi.org/10.3390/ijms21134800 |
Ejemplares similares
-
Enhanced anticancer effects of a methylation inhibitor by inhibiting a novel DNMT1 target, CEP 131, in cervical cancer
por: Kim, Dong Hyun, et al.
Publicado: (2019) -
Phosphorylation of β‐catenin Ser60 by polo‐like kinase 1 drives the completion of cytokinesis
por: Yu, Ji Eun, et al.
Publicado: (2021) -
p62-Induced Cancer-Associated Fibroblast Activation via the Nrf2-ATF6 Pathway Promotes Lung Tumorigenesis
por: Kang, Ji In, et al.
Publicado: (2021) -
Cep131 overexpression promotes centrosome amplification and colon cancer progression by regulating Plk4 stability
por: Kim, Dong Hyun, et al.
Publicado: (2019) -
Data analysis to evaluate the CPPF system in CMS trigger phase-I upgrade
por: CMS Collaboration
Publicado: (2018)